Compare CSBR & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSBR | COEP |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.7M | 91.2M |
| IPO Year | 2015 | N/A |
| Metric | CSBR | COEP |
|---|---|---|
| Price | $5.90 | $16.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.2K | ★ 52.9K |
| Earning Date | 03-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,900,000.00 | N/A |
| Revenue This Year | $4.84 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.50 | $6.80 |
| 52 Week High | $9.63 | $21.41 |
| Indicator | CSBR | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 48.75 | 72.18 |
| Support Level | $5.50 | $13.77 |
| Resistance Level | $6.28 | $19.19 |
| Average True Range (ATR) | 0.27 | 1.15 |
| MACD | 0.01 | 0.47 |
| Stochastic Oscillator | 34.40 | 87.62 |
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.